MorphoSys AG
MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid t… Read more
MorphoSys AG - Asset Resilience Ratio
MorphoSys AG (MPSYF) has an Asset Resilience Ratio of 27.27% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2023)
This chart shows how MorphoSys AG's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down MorphoSys AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $499.52 Million | 27.27% |
| Total Liquid Assets | $499.52 Million | 27.27% |
Asset Resilience Insights
- Very High Liquidity: MorphoSys AG maintains exceptional liquid asset reserves at 27.27% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
MorphoSys AG Industry Peers by Asset Resilience Ratio
Compare MorphoSys AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
| No industry peers found with asset resilience data. | ||
Annual Asset Resilience Ratio for MorphoSys AG (2012–2023)
The table below shows the annual Asset Resilience Ratio data for MorphoSys AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 25.87% | $524.26 Million | $2.03 Billion | +4.81pp |
| 2022-12-31 | 21.06% | $504.82 Million | $2.40 Billion | -12.99pp |
| 2021-12-31 | 34.05% | $870.42 Million | $2.56 Billion | -25.03pp |
| 2020-12-31 | 59.08% | $980.52 Million | $1.66 Billion | +13.12pp |
| 2019-12-31 | 45.97% | $228.19 Million | $496.44 Million | -12.22pp |
| 2018-12-31 | 58.19% | $313.50 Million | $538.76 Million | +37.36pp |
| 2017-12-31 | 20.83% | $86.54 Million | $415.40 Million | +5.76pp |
| 2016-12-31 | 15.08% | $69.89 Million | $463.60 Million | -9.27pp |
| 2015-12-31 | 24.35% | $97.41 Million | $400.08 Million | -2.27pp |
| 2014-12-31 | 26.62% | $113.53 Million | $426.48 Million | -17.94pp |
| 2013-12-31 | 44.56% | $199.46 Million | $447.66 Million | +9.01pp |
| 2012-12-31 | 35.54% | $79.72 Million | $224.29 Million | -- |